



# WORLD NEUROSCIENCE INNOVATION FORUM

---

27 March 2017 | LONDON

[neuroscienceinnovationforum.org](http://neuroscienceinnovationforum.org)

**PARTNERS**  
HEALTHCARE


FOUNDED BY BRIGHAM AND WOMEN'S HOSPITAL  
AND MASSACHUSETTS GENERAL HOSPITAL



# CONTENTS

---

<b>4</b>	Introductions
<b>9</b>	Information
<b>10</b>	Steering Committee
<b>13</b>	Springboard Challenge
<b>14</b>	Agenda
<b>22</b>	Sponsors
<b>26</b>	Planning Committee
<b>27</b>	Map



## Dear Innovation Leaders,

---

This is an unprecedented era in neuroscience. The pipeline of novel technologies and therapies for neurodegenerative and neuroinflammatory disorders continues to evolve as we work to find new cures and disease-modifying treatments. At the same time, never have the human and economic burdens of neurological disease been so large. Dementia, multiple sclerosis, Parkinson's disease, and related diseases create an almost incalculable chronic burden on patients, their families, and society. Globally, over 46 million people suffer dementia, and by 2030, almost 75 million people will suffer from this disease contributing to a cost of care estimated at 1 percent of the global GDP. For dementia and these debilitating central nervous system diseases, the global health care system is committed to providing the next generation of treatments and therapies to address the unmet care needs.

Today's World Neuroscience Innovation Forum is brought to you by Partners HealthCare, a Boston-based non-profit hospital system that includes Brigham Health, Massachusetts General Hospital and McLean Hospital. It is the largest academic research entity in the United States and its faculty are appointed at Harvard Medical School. Partners is dedicated to improving patient care through teaching, research, and collaborative innovation.

This Forum extends that to highlight new insights, therapeutic paths and collaborations designed to combat neuroinflammation and neurodegeneration. Throughout the day, the clinicians, scientists, industry executives and investors who are shaping the future of the field will explore the most promising technology and care. We are delighted to share this event with you today.

We would like to express our deepest appreciation to the many individuals who made this Forum possible. We are particularly grateful to our speakers—including CEOs and top executives of global medical companies, investors, government leaders, and scientific experts—for sharing their substantial expertise and unique perspectives with us today. The generous support provided by our leading sponsors—Biogen, Eli Lilly, GSK, Pfizer, The Francis Crick Institute, the High Lantern Group, Imperial College Health Partners, Janssen Neuroscience, and MedCity—have made this initiative possible.

Finally, we want to recognize the Steering Committee whose insights and standing in the field made the Forum possible. Additionally, we are grateful to the Planning Team, especially Anika Heavener, whose dedicated work over the last 12 months shaped every aspect of this new undertaking.

Thank you for bringing your own expertise to today's Forum!



**Anne Klibanski, MD**

Chief Academic Officer,  
Partners HealthCare



**Christopher Coburn**

Chief Innovation Officer,  
Partners HealthCare

## Welcome to the Francis Crick Institute,

---

I would like to personally welcome each of you to the 2017 World Neuroscience Innovation Forum and to the Francis Crick Institute's new state-of-the-art building here in the heart of London. The new facility delivers on the mission of the Crick to understand the fundamental biology underpinning health and disease. This world-class centre of biomedical research and innovation is dedicated to research excellence, and it has the scale, vision and expertise to tackle challenging scientific questions in neuroscience. We share a similar ambition to the Forum to promote innovation and connections between researchers, academic institutions, healthcare organisations and businesses.

It is an exciting time for us as an organisation as we look to champion the future of medical research and healthcare. I hope that you enjoy today's visit to the Francis Crick Institute and that we will see you again soon.



**Sir David Cooksey**

Chairman,  
The Francis Crick Institute





Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

***Biogen welcomes you to the 2017 World Neuroscience Innovation Forum***

**[www.biogen.com](http://www.biogen.com)**



Caring Deeply. Changing Lives.™



**Biogen**™



# It begins with a promise

to respect each other and the people we serve.

From the beginning, respect for people has been one of our company's fundamental values, a principle central to our culture and our mission to make life better for people around the world. In all we do, from our patient-support programs to our workplace practices to our corporate social responsibility initiatives, we strive to bring this value to life. Our humanity guides how we treat the people we serve. It inspires us to build trust through our commonalities, to celebrate our differences, and seek out the unique ways to make life better for everyone.

To find out more about our promise, visit [www.lilly.co.uk](http://www.lilly.co.uk).

©2017, Eli Lilly and Company. ALL RIGHTS RESERVED.

*Lilly*



# INFORMATION

## REGISTRATION HOURS

Monday, 27 March 07:30 – 08:30

## NAME BADGES

Name badges are available at registration and must be worn at all times to comply with the security measures at the Francis Crick Institute. The colored dot on each badge indicates lunch breakout assignments – the key for this is listed in the Forum agenda. Please return your badge to the registration desk for recycling at the close of the day.

## WIRELESS ACCESS

Connect to Wifi Guest network on your device

Open your browser and go to a non-secure website: <http://bbc.co.uk>

Tap 'Get online at The Francis Crick Institute'

If you have not used The Cloud before, tap 'Create Account' and enter your details

If you have used The Cloud elsewhere, you can use the email and password that you have previously set up and tap 'Continue'

You are now connected to the guest wifi

## AUDIENCE Q&A – JOIN THE CONVERSATION

To participate in the Q&A, please visit [www.slido.com](http://www.slido.com) and enter the event code #WNIF. Panel moderators will receive the submitted questions.

## SPEAKER BIOS

A complete list of speakers and their bios are available online via the agenda page of our website at: [neuroscienceinnovationforum.org/speakers](http://neuroscienceinnovationforum.org/speakers)

## SOCIAL

Be sure to keep up to date with us on our various social platforms:



WEB  
[neuroscienceinnovationforum.org](http://neuroscienceinnovationforum.org)



LINKEDIN  
Partners HealthCare Innovation




TWITTER  
@PartnersInnov



YOUTUBE  
World Medical Innovation Forum

# STEERING COMMITTEE



## Anne Klibanski, MD

Chief Academic Officer, Partners HealthCare; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School

Forum Chair



WORLD NEUROSCIENCE  
INNOVATION  
FORUM

LONDON



## Paul Anderson, MD, PhD

Chief Academic Officer and SVP of Research, Brigham and Women's Hospital; K. Frank Austen Professor of Medicine, Harvard Medical School



## Kate Bingham

Managing Partner, SVLS



## Merit Cudkowicz, MD

Chair of Neurology, Massachusetts General Hospital; Julianne Dorn Professor of Neurology, Harvard Medical School



## Jean-François Formela, MD

Partner, Atlas Venture



## Brad Hyman, MD, PhD

Director, MGH Alzheimer's Disease Research Center, Massachusetts General Hospital; John B. Penny, Jr. Professor Neurology, Harvard Medical School



## Philip Iredale, PhD

VP, Head of Circuits, Neuro-Opportunities & Screening, Technologies, Pfizer



## Ole Isacson, MD, PhD

Principal Investigator Harvard Stem Cell Institute, McLean Hospital; Professor of Neurology and Neuroscience, Harvard Medical School



## Husseini Manji, MD

Global Therapeutic Head, Neuroscience, Janssen R&D



## John McDonald

VP, Business Development, Biogen



## Harry Orf, PhD

SVP for Research, MassGeneral Research Institute, Massachusetts General Hospital



## Kerry Ressler, MD, PhD

Chief Scientific Officer, McLean Hospital; Professor in Psychiatry, Harvard Medical School



## David Roblin, MD

COO and Director of Scientific Translation, The Francis Crick Institute



## Martin Samuels, MD

Chair, Department of Neurology, Brigham and Women's Hospital; Miriam Sydney Joseph Professor of Neurology, Harvard Medical School



## Nadeem Sarwar, MD, PhD

President, AiM Institute, Eisai



## Dennis Selkoe, MD

Co-Director, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School



## David Silbersweig, MD

Chairman, Brigham and Women's Hospital; Stanley Cobb Professor of Psychiatry, Harvard Medical School



## Susan Slaughaupt, PhD

Elizabeth G. Riley and Dan E. Smith, Jr. MGH Research Scholar, Scientific Director of the Mass General Research Institute, Massachusetts General Hospital; Professor of Neurology, Harvard Medical School



## Reisa Sperling, MD

Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital; Professor of Neurology, Harvard Medical School



## Rudolph Tanzi, PhD

Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital; Joseph. P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School



## Frank Tarazi, PhD

Director, Psychiatric Neuroscience Program, McLean Hospital; Associate Professor of Psychiatry and Neuroscience, Harvard Medical School



## Howard Weiner, MD

Director, Multiple Sclerosis Program, Brigham and Women's Hospital; Robert L. Kroc Professor of Neurology, Harvard Medical School



*Hong Hu, Research Advisor,  
Lilly Research Laboratories*

# It begins with a promise to discover medicines that make life better.

Since 1876, we have worked tirelessly to develop and deliver trusted medicines that meet real needs, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our promise, visit [www.lilly.co.uk](http://www.lilly.co.uk).

©2017, Eli Lilly and Company. ALL RIGHTS RESERVED.

*Lilly*



Dennis  
Dennis Selkoe, MD  
BRIGHAM AND WOMEN'S  
HOSPITAL  
SPEAKER



# Springboard

— CHALLENGE —



## We Welcome You to Apply

The Springboard Challenge is a planning grant program designed to convert the Forum's plenary panel discussions into action to address neurodegenerative (NDD) or neuroinflammatory (NID) diseases. The Challenge planning grants will establish new international, multi-sector teams dedicated to laying the groundwork for proposed solutions in NDD or NID. The Challenge offers three awards of \$50,000 each and provides mentorship support from leading UK and US venture capitalists. These awards are intended to fund team meetings, logistics, and strategic planning efforts for the proposed solution; they are not meant to support biomedical research.

The Springboard Challenge committee will review applications that address the following high-level award guidelines:

- Convene various stakeholders (3-5 individuals) from academia, clinical care, industry, foundations, patient advocacy, or government to address a significant unmet need highlighted at the World Neuroscience Innovation Forum;
- Aim for creative and ambitious solutions while articulating a viable strategy for implementation;
- Articulate a plan for follow-up funding support or partnership from third parties to implement their solution.

Applicants proposing a public-private partnership are encouraged to apply. International teams are also encouraged; awards will be made to a single team member based in the US or UK. For the complete list of criteria for the Springboard Challenge, please visit the Forum website: [neuroscienceinnovationforum.org/springboard-challenge](http://neuroscienceinnovationforum.org/springboard-challenge)

### TIMELINE

The application window for the Springboard Challenge is open until 1 June 2017. Please submit applications to Nelson Medeiros, PhD ([namedeiros@partners.org](mailto:namedeiros@partners.org)). The Challenge selection committee will review applications and select awardees in late Summer/Fall 2017.

More information, including an application for the Springboard Challenge, is available at: [neuroscienceinnovationforum.org/springboard-challenge](http://neuroscienceinnovationforum.org/springboard-challenge)



WORLD NEUROSCIENCE  
INNOVATION  
FORUM  
LONDON

2015 WORLD MEDICAL INNOVATION FORUM

Neuroscience  
BOSTON, MA USA

# AGENDA

All speaker bios are at: [neuroscienceinnovationforum.org/speakers](http://neuroscienceinnovationforum.org/speakers)

07:30 – 08:30 Registration

08:30 – 08:50 Welcome

**Anne Klibanski, MD**, Chief Academic Officer, Partners HealthCare; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School  
**David Roblin, MD**, COO and Director of Scientific Translation, The Francis Crick Institute



08:50 – 09:05 Address from UK Dementia Envoy

**David Mayhew, CBE**, UK Dementia Envoy; Chairman, Alzheimer's Research UK



09:05 – 09:50 Session 1 | Disease Modifying Therapies:  
Getting Over the Technology Threshold

What are the investment priorities for new diagnostics and therapeutics?  
Are symptomatic therapies still viable?

#### MODERATOR

**Jean-François Formela, MD**, Partner, Atlas Venture

**Kate Bingham**, Managing Partner, SVLS

**Min Li, PhD**, SVP, Global Head of Neurosciences, GlaxoSmithKline

**Vivek Ramaswamy**, CEO, Roivant Sciences

**Alfred Sandrock, MD, PhD**, EVP, Chief Medical Officer, Head, Development and Worldwide Medical, Biogen

**Dennis Selkoe, MD**, Co-Director, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School





**09:50 – 10:35** Session 2 | Expanding the Diagnostic Spectrum: Tools, Technologies, and Tracers

The market for neurological diagnostics is growing rapidly and expected to reach \$13.6 billion by 2019. Which technologies will drive this new system? When will they be deployed and what are key barriers? Will there be sufficient discrete financial incentives to achieve the necessary innovation?

**MODERATOR**

**Bruce Rosen, MD, PhD**, Director, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

**Roger Gunn, PhD**, CSO, Imanova; Professor of Molecular Neuroimaging, Department of Medicine, Imperial College, London

**Jacob Hooker, PhD**, Phyllis and Jerome Lyle Rappaport MGH Research Scholar, Director of Radiochemistry, Athinoula A. Martinos Center, Massachusetts General Hospital; Associate Professor in Radiology, Harvard Medical School

**Robert Krieg, PhD**, VP of MR Product Definition & Innovation, Siemens

**Eddie Martucci, PhD**, CEO, Akili Interactive Labs

**Henrik Zetterberg, MD, PhD**, Professor of Neurochemistry, Head of Lab, UCL; Professor of Neurochemistry, Head of Department, University of Gothenburg



**10:35 – 10:55** Break

**10:55 – 11:20** 1:1 Fireside Chat with John Lechleiter

**MODERATOR**

**Hilary Evans**, CEO, Alzheimer’s Research UK

**John Lechleiter, PhD**, Chairman, Eli Lilly and Company



**11:20 – 11:45** Patient Interview

**Martin Samuels, MD**, Chair, Department of Neurology, Brigham and Women’s Hospital; Miriam Sydney Joseph Professor of Neurology, Harvard Medical School

**Brenda and Stephen Whittle, PhD**, Dementia Patient & Caregiver, Dementia Advocates and Volunteer Partners with ARUK (Alzheimer’s Research UK)



**11:45 – 12:30** Session 3 | Neurodegeneration and Neuroinflammation: A Grand Unifying Theory for Drug Development?

How will new immunity-focused insights and technologies drive neurodegeneration and neuroinflammatory diagnostics and therapies?

**MODERATOR**

**Rudolph Tanzi, PhD**, Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School


**Christian Haass, PhD**, Institute Head, German Center for Neurodegenerative Disease

**Michael Hayden, MD, PhD**, President of Global R&D, CSO, Teva Pharmaceutical Industries

**Michael Hutton, PhD**, CSO, Neuroscience, Eli Lilly and Company

**Roger Nitsch, MD**, President, Neurimmune Holding AG

**Hugh Perry, PhD**, Professor of Experimental Neuropathology, University of Southampton



## LUNCH BREAKOUTS

### 12:30 – 13:40 Lunch Breakout 1 | Women and Dementia

#### SEMINAR SUITES

Women have unique brain health challenges as they are twice as likely as men to have dementia. Additionally, women often take on the responsibility of caring for a loved one with the disease. This breakout will explore the efforts in sex-based brain health research and current funding challenges.

#### MODERATOR

**Phyllis Ferrell**, VP, Global Alzheimer's Disease Platform Team, Eli Lilly and Company

**Hilary Evans**, CEO, Alzheimer's Research UK

**Reisa Sperling, MD**, Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital; Professor of Neurology, Harvard Medical School

**Jill Lesser**, President of WomenAgainstDementia



### 12:30 – 13:40 Lunch Breakout 2 | Evolving Dementia Care: Government Policy in Action

#### WELLCOME AUDITORIUM 1

How are the national dementia care strategies evolving? How does dementia care impact therapeutic innovation? Are we monitoring the impact of care beyond quality of life measures?

#### MODERATOR

**Tim Ferris, MD**, Senior Vice President of Population HealthCare Management, Partners HealthCare; Associate Professor of Medicine and Pediatrics, Harvard Medical School

**Geoff Huggins**, Director of Health Social Care and Integration, Scottish Government

**Marc Wortmann**, Executive Director, Alzheimer's Disease International



### 12:30 – 13:40 Lunch Breakout 3 | Depression and Neuroinflammation

#### WELLCOME AUDITORIUM 2

Depressed patients often have high levels of inflammatory biomarkers, supporting the idea that certain psychiatric disorders could be an inflammatory response. As over half of all people with depression do not respond to conventional therapies, this breakout will explore the emerging research in anti-inflammatory treatments for CNS.

#### MODERATOR

**Philip Iredale, PhD**, VP Head of Circuits, Neuro-Opportunities & Screening, Technologies, Pfizer

**Declan Jones, PhD**, VP, Neuroscience Lead, J&J London Innovation Centre, Johnson & Johnson

**Kerry Ressler, MD, PhD**, CSO, McLean Hospital; Professor in Psychiatry, Harvard Medical School



### 12:30 – 13:40 Lunch Breakout 4 | Networking in Open Area

#### GALLERY





**13:40 – 14:25** Session 4 | The Promise and Current Role of Gene and Cell Therapy as Treatments of Neurological Disease

Which diseases will be first? What are the barriers?  
When will there be clinical deployment?

**MODERATOR**

**Ole Isacson, MD, PhD**, Principal Investigator Harvard Stem Cell Institute, McLean Hospital; Professor of Neurology and Neuroscience, Harvard Medical School

**Timothy Cox, MD**, Professor of Medicine Emeritus, Director of Research, Honorary Consultant Physician, University of Cambridge

**Brad Hyman, MD, PhD**, Director, Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital; John B. Penney Professor of Neurology, Harvard Medical School

**Gillian Leng, MD**, Deputy Chief Executive, National Institute for Health and Care Excellence

**Steven Paul, MD**, CEO, Voyager Therapeutics



**14:25 – 15:10** Session 5 | Next-Generation Therapies and Diagnostics: Big Data and Digital Health

As new HIT-driven systems and products are identified, what will influence new therapies and diagnostics? Which technologies will scale the fastest?  
How large do cohorts have to be to provide meaningful insights?  
Are there examples of real world successes?

**MODERATOR**

**Shawn Murphy, MD, PhD**, Corporate Director of Research Information Systems and Computing, Partners HealthCare; Associate Professor of Neurology, Harvard Medical School

**Jenny Barnett, PhD**, CSO, Cambridge Cognition

**John Gallacher, PhD**, Director, MRC Dementias Platform UK

**Hussein Manji, MD**, Global Therapeutic Area Head, Neuroscience, Janssen R&D

**Richard Rudick, MD**, VP Development Sciences, Biogen

**Howard Weiner, MD**, Director, Multiple Sclerosis Program, Brigham and Women's Hospital; Robert L. Kroc Professor of Neurology, Harvard Medical School



All speaker bios are at: [neuroscienceinnovationforum.org/speakers](https://neuroscienceinnovationforum.org/speakers)



2015 WORLD MEDICAL INNOVATION FORUM  
Neuroscience  
BOSTON, MA USA

All speaker bios are at: [neuroscienceinnovationforum.org/speakers](http://neuroscienceinnovationforum.org/speakers)

15:10 – 15:35 1:1 Fireside Chat

**Michael Ehlers, MD, PhD**, EVP, Head of R&D, Biogen



15:35 – 15:55 Break

15:55 – 16:40 Session 6 | Implementing Novel Models in Alzheimer's Trials:  
How Can We Transform the Cost-Benefit Equation for Trials?

With an expanding Alzheimer's pipeline, design challenges continue to limit the flexibility of trial execution. Which emerging solutions (e.g. digital technologies, data sharing, patient recruitment, alternative endpoints) will transform cost, duration, or value generated from future Alzheimer's trials?

**MODERATOR**

**Reisa Sperling, MD**, Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital; Professor of Neurology, Harvard Medical School

**Iain Chessell, PhD**, VP Neuroscience IMED MedImmune, AstraZeneca

**Michael Krams, MD**, Global Head of Quantitative Sciences, Janssen Pharmaceuticals

**Craig Ritchie, MD, PhD**, Professor of Psychiatry of Ageing University of Edinburgh

**Nadeem Sarwar, MD, PhD**, President, AiM Institute, Eisai



**16:40 – 17:25** Session 7 | The Crisis We Want: Are Healthcare Systems Prepared for a Disease-Modifying Drug?

There are currently 17 Alzheimer's drugs entering Phase III over the next five years. What will be the response from payors, clinicians, and patient groups when those drugs finally reach patients? How can we find, treat, and provide drug access to all the right patients?

**MODERATOR**

**Merit Cudkowicz, MD**, Chair, Department of Neurology, Massachusetts General Hospital; Julieanne Dorn Professor of Neurology, Harvard Medical School

**Phyllis Ferrell**, VP, Global Alzheimer's Disease Platform Team, Eli Lilly and Company

**Tim Ferris, MD**, Senior Vice President of Population HealthCare Management, Partners HealthCare; Associate Professor of Medicine and Pediatrics, Harvard Medical School

**Geoff Huggins**, Director of Health Social Care and Integration, Scottish Government

**Bob Oliver**, CEO, Otsuka America Pharmaceutical



**17:25 – 18:00** Announcement and Discussion of the Springboard Challenge

**MODERATOR**

**Christopher Coburn**, Chief Innovation Officer, Partners HealthCare

**John Lepore, MD**, SVP, R&D Pipeline GlaxoSmithKline



**18:00 – 18:15** Forum Close

**Paul Anderson, MD, PhD**, Chief Academic Officer and SVP of Research, Brigham and Women's Hospital; K. Frank Austen Professor of Medicine, Harvard Medical School

**Harry Orf, PhD**, SVP for Research, MassGeneral Research Institute, Massachusetts General Hospital



**18:15 – 20:00** Reception

*\*Panels and speakers are subject to change.*

# IDEAS THAT CHANGE LIVES

The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease.

Our work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.

We are based in a brand new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making us the biggest biomedical research facility under a single roof in Europe.

Our world-leading researchers range from the most promising early-career scientists to distinguished international figures, including three Nobel Laureates, two Lasker award winners, eight winners of the Louis-Jeantet Prize for Medicine, 20 Fellows of the Royal Society and 28 Fellows of the Academy of Medical Sciences.

[WWW.CRICK.AC.UK](http://WWW.CRICK.AC.UK)



We are an independent organisation, with six founding partners: the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King's College London.





do more  
feel better  
live longer

## **GSK neuroscience**

*Global R&D, novel approach, open innovation*

GSK has invested in neuroscience for decades and we remain focused on discovering and developing differentiated medicines to treat neurological disorders and address unmet medical needs. We have full capabilities, from early-stage target identification through post-marketing studies, and firmly believe we have the potential to make a difference.

Our research is focused on exploring new therapies to treat, modify or halt neurological diseases. Our approach is unique in that therapeutics targeting hyper-excitatory responses may be useful to patients suffering from neurodegenerative conditions. The pursuit of acute indications, such as pain, alongside chronic, progressive conditions, like Alzheimer's and Parkinson's diseases, creates a strategically balanced approach, fostering scientific synergy and mitigating business risks.

We are committed to open innovation and strategic collaboration. Our Neuro2020 program encourages open innovation and partnerships between GSK and academics in order to stay at the forefront of scientific discovery and accelerate the development of new medicines for patients because we know we cannot take on the world's healthcare challenges alone.

For more information, visit **[www.gsk.com](http://www.gsk.com)**.

# SPONSORS

## Thank You.

The 2017 World Neuroscience Innovation Forum was made possible through the generosity of the following sponsors.



## PRESENTING



## Biogen

CAMBRIDGE, MASSACHUSETTS; USA

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world's oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit [www.biogen.com](http://www.biogen.com). Follow us on Twitter (@biogen).

[www.biogen.com](http://www.biogen.com)

## STAKEHOLDER



## Eli Lilly and Company

INDIANAPOLIS, INDIANA; USA

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at [www.lilly.com](http://www.lilly.com) and [newsroom.lilly.com/social-channels](http://newsroom.lilly.com/social-channels).

[www.lilly.com](http://www.lilly.com)

## STRATEGIC



GlaxoSmithKline  
BRENTFORD,  
UNITED KINGDOM

[www.gsk.com](http://www.gsk.com)



Pfizer  
NEW YORK CITY,  
NEW YORK; USA

[www.pfizer.com](http://www.pfizer.com)



The Francis Crick Institute  
LONDON, UNITED KINGDOM

[www.crick.ac.uk](http://www.crick.ac.uk)

## COLLABORATORS





*Before it became a medicine,  
It was 5,000 researched compounds.*

*87 different protein structures.*

*500,000 lab tests.*

*1,600 scientists.*

*80-hour workweeks.*

*14 years of breakthroughs and setbacks.*

*36 clinical trials.*

*8,500 patient volunteers.*

*And more problems to solve than we could count.*

*Before it became a medicine,  
It was an idea in the mind of a Pfizer scientist.*

*Now it's a medicine  
That saves lives every day.*



*Driven to discover the cure*



HLG

High Lantern Group  
is proud to support  
the work of  
UsAgainstAlzheimers,  
Global CEOi Initiative  
on Alzheimer's,  
WomenAgainstAlzheimer's,  
Global Coalition on Aging,  
& private sector  
companies investing  
to stop Alzheimer's.

HighLanternGroup.com

Washington DC | New York | Los Angeles  
Philadelphia | Geneva

IMPERIAL COLLEGE  
HEALTH PARTNERS

Unleashing the power of  
**collaboration, experimentation**  
and **innovation** in healthcare.

We exist to create the space and energy  
for innovation in healthcare. We specialise  
in transformational change, capability  
building and systems leadership.

Get in touch with us  
today to discover how  
we can help.

@ldn\_ichp 0207 960 6241

linkedin/imperialcollegehealthpartners

www.imperialcollegehealthpartners.com



**Collaboration.**  
Now that's what we call a medical breakthrough.

At Janssen, we seek answers to some of the toughest questions in medicine.

We believe nothing is more powerful than collaboration. There should not be barriers in the pursuit of groundbreaking treatments. Collaboration goes beyond new treatments.

From early discovery to access and distribution, we seek partners who want the same things we do: better outcomes for our patients.

Our mission drives us. Our patients inspire us. We collaborate with the world for the health of everyone in it.

www.janssen.com

janssen Neuroscience

PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Janssen Research & Development, LLC © 2017, JRD

MedCity

MedCity exists to promote and grow life sciences investment, entrepreneurship, collaboration and industry in Cambridge London, Oxford and the greater south east.

**How we can work with you**

Whatever your need or the stage of your business, MedCity can help you navigate the richness of the greater south east's life sciences ecosystem.

Our support includes:

- Matching you to the right academic, clinical and industry partners
- Helping you locate facilities and work spaces
- Supporting you in setting up clinical trials
- Guiding you through regulatory and procurement processes
- Connecting you with influential networks

@MedCityHQ  
medcityhq.com



## 2017 WORLD NEUROSCIENCE INNOVATION FORUM

# PLANNING COMMITTEE

A special thanks to the Planning Committee staff for their unstinting commitment over the last 12 months to create the 2017 World Neuroscience Innovation Forum.

### PLANNING COMMITTEE



**Christopher Coburn**  
Chief Innovation Officer, Innovation,  
Partners HealthCare



**Anika Heavener**  
Senior Manager, Business  
Development and Strategic Alliances



**Nelson Medeiros, PhD**  
Senior Licensing Manager



**Beth Mollineaux**  
General Manager, Strategic Marketing  
and Communications



**Diana Schwartzstein**  
Director of Administration

### EVENT TEAM

**Jamie Belkin**

**Eric Castle**

**Gerald Couzens**

**Madeleine Halle**


**Cass Jerman**

**Jerry Mizer**

**Greg Mueller**

**Lisa Savin**

# MAP



## Accelerating your neurodegeneration research into patient treatments

Gain access to development funding, drug discovery, diagnostic development, and scientific & commercial partnerships.

Find out more about how we can help you at

[mrctechnology.org/neuro](http://mrctechnology.org/neuro)

## Innovating Cardiac Care On A Global Scale.

Join us at our annual flagship event, the World Medical Innovation Forum.

Be a part of the drive to redefine cardiovascular and cardiometabolic care—the largest market in healthcare—through new therapies, digital diagnostics, 'omics, platforms, and engagement.

To join fellow decision makers at the World Medical Innovation Forum, please follow the link to register: [worldmedicalinnovation.org](http://worldmedicalinnovation.org)

**CARDIOVASCULAR | MAY 1–3, 2017  
BOSTON, MA USA**

WORLD MEDICAL  
**INNOVATION**  
FORUM™





Partners HealthCare Innovation  
215 First Street, Suite 500  
Cambridge, MA 02142  
USA

00 1 857 307 2400 | [innovation.partners.org](http://innovation.partners.org)

